{"id":"NCT02367911","sponsor":"Therapeutics, Inc.","briefTitle":"A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis","officialTitle":"A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01","primaryCompletion":"2015-08","completion":"2017-02","firstPosted":"2015-02-20","resultsPosted":"2018-09-27","lastUpdate":"2018-11-08"},"enrollment":144,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Plaque Psoriasis"],"interventions":[{"type":"DRUG","name":"122-0551 Foam","otherNames":[]},{"type":"DRUG","name":"Vehicle Foam","otherNames":[]}],"arms":[{"label":"Active Arm","type":"EXPERIMENTAL"},{"label":"Vehicle Arm","type":"PLACEBO_COMPARATOR"}],"summary":"This Phase 3 study has been designed to determine and compare the efficacy and safety of 122-0551 Foam and Vehicle Foam applied twice daily for two weeks in subjects with plaque psoriasis.","primaryOutcome":{"measure":"Percentage of Subjects Rated a \"Treatment Success\" Based on the Investigator's Global Assessment (IGA)","timeFrame":"Day 15","effectByArm":[{"arm":"Active Arm","deltaMin":18.3,"sd":null},{"arm":"Vehicle Arm","deltaMin":9.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":9,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":71},"commonTop":["Application site dryness","Application site pain","Gastroenteritis viral","Sinusitis","Trichorrhexis"]}}